Clinical Trials Sponsored by Craig L Slingluff, Jr

Total 24 results

Craig L Slingluff, Jr

Completed

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59)

Melanoma

United States
Craig L Slingluff, Jr

Recruiting

Excision of Lymph Node Trial (EXCILYNT) (Mel69) (EXCILYNT)

Melanoma

United States
Craig L Slingluff, Jr

Recruiting

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101)

Pancreatic Cancer

United States
Craig L Slingluff, Jr

Terminated

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41)

Breast Cancer

United States
Craig L Slingluff, Jr

Terminated

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC)

Melanoma

United States
Craig L Slingluff, Jr

Completed

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (MEL39)

Melanoma

United States
Craig L Slingluff, Jr

Terminated

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma (Mel 51)

Melanoma

United States
Craig L Slingluff, Jr
University of Virginia

Completed

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (MEL60)

Melanoma | Metastatic Melanoma | Mucosal Melanoma

United States
Craig L Slingluff, Jr

Completed

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma (MEL37)

Melanoma

United States
Craig L Slingluff, Jr
Theraclion

Active, not recruiting

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003)

Melanoma | Cervical Cancer | Breast Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability High | Squamous Cell Cancer

United States
Craig L Slingluff, Jr
GlaxoSmithKline

Completed

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (Mel55)

Melanoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Completed

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)

Melanoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Active, not recruiting

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)

Melanoma | Ocular Melanoma | Uveal Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)

Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Colorectal Cancer

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer (Breast 37)

Breast Neoplasms

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (Mel64)

Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Advanced Melanoma (Mel48)

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI); University of Virginia; Oncovir, Inc.

Completed

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

Melanoma

United States
Craig L Slingluff, Jr
Cancer Research Institute, New York City; Ludwig Institute for Cancer Research

Terminated

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (Mel63; CHAMP)

Melanoma

United States

3

Subscribe